Life-Threatening Complications in Cancer Patients in the ICU During Immunotherapy

Background

Immunotherapy has introduced a range of life-threatening complications that require specialized ICU care. Understanding these complications is essential for intensivists.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

• Immunotherapy can lead to hyperinflammatory syndromes, neurotoxicity, severe pneumonitis, and myocarditis.
• Complications from CAR-T therapy and immune checkpoint inhibitors often present with overlapping symptoms, complicating diagnosis.
• Timely ICU escalation and integrated supportive care are crucial for managing immunotherapy-related critical illnesses.
• Recognition of these complications requires parallel evaluation and serial reassessment in the ICU.

Clinical Implications

Intensivists must recognize the unique complications associated with immunotherapy, as they may mimic traditional ICU syndromes.

Conclusion

Immunotherapy-related critical illness is a growing concern in oncologic intensive care.

Related Resources & Content

1. The ASCO Post, 2017 -- Managing Toxicities Associated With Immunotherapy for Lung Cancer
2. Basic Research in Cardiology, 2024 -- Cardiovascular Adverse Events Related to Immunotherapy: An Overlooked Risk for Cancer Patients
3. Intensive Care Medicine, 2024 -- Emergency Chemotherapy Administration for Hematological Patients in Intensive Care Settings
4. 2025 ESC Guidelines for the management of myocarditis and pericarditis | European Heart Journal | Oxford Academic
5. How should immune checkpoint inhibitor myocarditis be treated? | Cardio-Oncology | Springer Nature Link
6. Immune checkpoint inhibitor-related neurotoxicity: Incidence and management. A systematic review and meta-analysis - PubMed
7. The ASCO Post — Pearls for Managing Immune-Related Toxicities
8. 2025 ESC Guidelines for the management of myocarditis and pericarditis | European Heart Journal | Oxford Academic
9. How should immune checkpoint inhibitor myocarditis be treated? | Cardio-Oncology | Springer Nature Link
10. Immune checkpoint inhibitor-related neurotoxicity: Incidence and management. A systematic review and meta-analysis - PubMed
11. https://www.astct.org/Education/Practice-Guidelines?utm_source=openai
12. Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee | Bone Marrow Transplantation
13. Sequential Bispecific Antibodies and CAR-T Use Is a Safe and Effective Strategy in Relapsed Refractory Hematologic Malignancies - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
14. Comparative Risks of Pneumonitis Amongst Immune Checkpoint Inhibitors in Patients with Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials - PMC
15. Management of Clostridioides difficile infection in patients with haematological malignancies and after cellular therapy: guidelines from 10th European Conference on Infections in Leukaemia (ECIL-10) - PubMed